BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會


Choi Jae Yeon


Session 12 – Recent Development of Game-Changing Tumor Agnostic Therapeutics

Date:23 July (Friday)
Time:  12:20 – 13:50 (GMT+8)

Choi Jae Yeon

Managing Director
Merck Sharp & Dohme (I.A.) LLC, Taiwan Branch

Jae Yeon Choi is Managing Director of MSD Taiwan and pursuing the aspiration with team to make positive impact on more patients in Taiwan.

In March 2017, Jae Yeon joined MSD as External Affairs Lead, Korea, and focused on strengthening the External Affairs team in alignment with our company’s strategy of upgrading Korea’s Market Access, Policy, and Communication capabilities. Concurrently, she also led a cross-functional team for Oncology portfolio reimbursement, where she drove a significant improvement in the speed of access to patients. 

Jae Yeon then moved into the role of the Oncology Business Unit Director in Korea – where she developed and led a high-performing and award-winning team that achieved and maintained the #1 position in sales in the Immuno-oncology market since Q2 2018; the total Oncology market since Q2 2019; and the total pharmaceutical market since Q1 2020.

Prior to MSD, Jae Yeon was the Marketing Director at Lilly Korea, responsible for managing products and portfolio strategy, digital marketing, and market research across diverse geographies including the US, China, and Korea. She also received numerous recognitions, including the Lilly Research Laboratory President Award (US), Best Coaching Award (Korea), and Medical Representative of the Year (China).

Jae Yeon holds a Bachelor of Arts in French from Hankuk University of Foreign Studies in Korea, and an MBA from Kellogg School of Business, Northwestern University in the US. 

Speech title & Synopsis

Panel Discussion & Closing Remarks